Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study ...

Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population Strong correlation observed between mRFS an ...

Elicio Therapeutics (ELTX) presented updated results from the Phase 1 AMPLIFY-201 clinical trial of ELI-002, an Amphiphile, AMP, cancer vaccine that targets KRAS-mutant tumors, at the ESMO ...